A China precision-oncology leader priced for distress—Burning Rock’s in-hospital kit model is nearing profitability, but VBP and execution speed decide the outcome.
Overview
Burning Rock Biotech (BNR), founded in 2014 in Guangzhou, is repositioning from a high-burn precision oncology testing provider into a scalable, product-centric NGS diagnostics platform. It operates across Central Lab testing, In-Hospital deployment, and Pharma R&D services, with the strategic center of gravity shifting toward in-hospital labs within Tier 3 hospitals. This model monetizes through kit/reagent sales, proprietary equipment, and recurring software/maintenance, aiming to capture higher-margin, repeatable revenue while hospitals supply space and personnel. Burning Rock differentiates via regulatory first-mover NMPA approvals for NGS kits, integrated automation, and a pharma CDx ecosystem that can embed tests into drug labels. Financially, 2025 showed a profitability inflection: RMB 539.6M revenue (+4.6%), gross margin 74.7%, opex down 36%, net loss down 84%, and first positive adjusted EBITDA in Q4 2025—supporting the view that the business model transition is reaching critical mass.